Escherichia coli Infections – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Escherichia coli Infections – Pipeline Review, H1 2020’, provides an overview of the Escherichia coli Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections

– The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects

– The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ABAC Therapeutics SA

Affilogic SAS

AstraZeneca Plc

Atterx Biotherapeutics Inc

BB100 LLC

Biomendics LLC

Bugworks Research India Pvt Ltd

ContraFect Corp

Debiopharm International SA

Eligo Bioscience SA

Eligochem Ltd

EnBiotix Inc

EveliQure Biotechnologies GmbH

F. Hoffmann-La Roche Ltd

Forge Therapeutics Inc

GlyProVac ApS

Hsiri Therapeutics LLC

Immuron Ltd

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Linnaeus Bioscience Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Navigen Inc

Neoculi Pty Ltd

Northern Antibiotics Oy

Nosopharm SAS

Novabiotics Ltd

Ostrich Pharma USA Inc

Oxford Drug Design Ltd

Paratek Pharmaceuticals Inc

Phico Therapeutics Ltd

Procarta Biosystems Ltd

Protein Potential LLC

Pylum Biosciences Inc

Recce Pharmaceuticals Ltd

RemAb Therapeutics SL

Sealife PHARMA GMBH

Shanghai Space Peptides Pharmaceutical Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Syntiron LLC

TCM Biotech International Corp

Venus Medicine Research Center

Table of Contents

Table of Contents

Introduction

Escherichia coli Infections - Overview

Escherichia coli Infections - Therapeutics Development

Escherichia coli Infections - Therapeutics Assessment

Escherichia coli Infections - Companies Involved in Therapeutics Development

Escherichia coli Infections - Drug Profiles

Escherichia coli Infections - Dormant Projects

Escherichia coli Infections - Discontinued Products

Escherichia coli Infections - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Escherichia coli Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Escherichia coli Infections – Pipeline by ABAC Therapeutics SA, H1 2020

Escherichia coli Infections – Pipeline by Affilogic SAS, H1 2020

Escherichia coli Infections – Pipeline by AstraZeneca Plc, H1 2020

Escherichia coli Infections – Pipeline by Atterx Biotherapeutics Inc, H1 2020

Escherichia coli Infections – Pipeline by BB100 LLC, H1 2020

Escherichia coli Infections – Pipeline by Biomendics LLC, H1 2020

Escherichia coli Infections – Pipeline by Bugworks Research India Pvt Ltd, H1 2020

Escherichia coli Infections – Pipeline by ContraFect Corp, H1 2020

Escherichia coli Infections – Pipeline by Debiopharm International SA, H1 2020

Escherichia coli Infections – Pipeline by Eligo Bioscience SA, H1 2020

Escherichia coli Infections – Pipeline by Eligochem Ltd, H1 2020

Escherichia coli Infections – Pipeline by EnBiotix Inc, H1 2020

Escherichia coli Infections – Pipeline by EveliQure Biotechnologies GmbH, H1 2020

Escherichia coli Infections – Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Escherichia coli Infections – Pipeline by Forge Therapeutics Inc, H1 2020

Escherichia coli Infections – Pipeline by GlyProVac ApS, H1 2020

Escherichia coli Infections – Pipeline by Hsiri Therapeutics LLC, H1 2020

Escherichia coli Infections – Pipeline by Immuron Ltd, H1 2020

Escherichia coli Infections – Pipeline by Johnson & Johnson, H1 2020

Escherichia coli Infections – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020

Escherichia coli Infections – Pipeline by Linnaeus Bioscience Inc, H1 2020

Escherichia coli Infections – Pipeline by Meiji Seika Pharma Co Ltd, H1 2020

Escherichia coli Infections – Pipeline by Melinta Therapeutics Inc, H1 2020

Escherichia coli Infections – Pipeline by Merck & Co Inc, H1 2020

Escherichia coli Infections – Pipeline by Microbiotix Inc, H1 2020

Escherichia coli Infections – Pipeline by Navigen Inc, H1 2020

Escherichia coli Infections – Pipeline by Neoculi Pty Ltd, H1 2020

Escherichia coli Infections – Pipeline by Northern Antibiotics Oy, H1 2020

Escherichia coli Infections – Pipeline by Nosopharm SAS, H1 2020

Escherichia coli Infections – Pipeline by Novabiotics Ltd, H1 2020

Escherichia coli Infections – Pipeline by Ostrich Pharma USA Inc, H1 2020

Escherichia coli Infections – Pipeline by Oxford Drug Design Ltd, H1 2020

Escherichia coli Infections – Pipeline by Paratek Pharmaceuticals Inc, H1 2020

Escherichia coli Infections – Pipeline by Phico Therapeutics Ltd, H1 2020

Escherichia coli Infections – Pipeline by Procarta Biosystems Ltd, H1 2020

Escherichia coli Infections – Pipeline by Protein Potential LLC, H1 2020

Escherichia coli Infections – Pipeline by Pylum Biosciences Inc, H1 2020

Escherichia coli Infections – Pipeline by Recce Pharmaceuticals Ltd, H1 2020

Escherichia coli Infections – Pipeline by RemAb Therapeutics SL, H1 2020

Escherichia coli Infections – Pipeline by Sealife PHARMA GMBH, H1 2020

Escherichia coli Infections – Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, H1 2020

Escherichia coli Infections – Pipeline by Soligenix Inc, H1 2020

Escherichia coli Infections – Pipeline by Spero Therapeutics Inc, H1 2020

Escherichia coli Infections – Pipeline by Syntiron LLC, H1 2020

Escherichia coli Infections – Pipeline by TCM Biotech International Corp, H1 2020

Escherichia coli Infections – Pipeline by Venus Medicine Research Center, H1 2020

Escherichia coli Infections – Dormant Projects, H1 2020

Escherichia coli Infections – Dormant Projects, H1 2020 (Contd..1), H1 2020

Escherichia coli Infections – Dormant Projects, H1 2020 (Contd..2), H1 2020

Escherichia coli Infections – Dormant Projects, H1 2020 (Contd..3), H1 2020

Escherichia coli Infections – Dormant Projects, H1 2020 (Contd..4), H1 2020

Escherichia coli Infections – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Escherichia coli Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports